Briacell Therapeutics Corp (BCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) has a cash flow conversion efficiency ratio of -0.268x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.11 Million) by net assets ($30.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Briacell Therapeutics Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Briacell Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Briacell Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Briacell Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ihlas Gazetecilik AS
IS:IHGZT
|
-0.003x |
|
UCAL Limited
NSE:UCAL
|
N/A |
|
Fortuna Metals Limited
AU:FUN
|
-0.024x |
|
SABUY TECHNOLOGY
BK:SABUY-R
|
N/A |
|
Nexus Minerals Ltd
AU:NXM
|
-0.347x |
|
Vmoto Ltd
AU:VMT
|
-0.010x |
|
Prologue
PA:ALPRG
|
-0.409x |
|
Minim Inc
NASDAQ:MINM
|
0.736x |
Annual Cash Flow Conversion Efficiency for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual cash flow conversion efficiency of Briacell Therapeutics Corp from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Briacell Therapeutics Corp.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $23.83 Million | $-39.07 Million | -1.639x | -118.54% |
| 2024-07-31 | $-3.73 Million | $-32.97 Million | 8.845x | +39.91% |
| 2023-07-31 | $-5.04 Million | $-31.89 Million | 6.322x | +627.54% |
| 2022-07-31 | $13.25 Million | $-15.87 Million | -1.198x | -319.15% |
| 2021-07-31 | $34.58 Million | $-9.89 Million | -0.286x | -166.16% |
| 2020-07-31 | $-3.60 Million | $-1.55 Million | 0.432x | -94.19% |
| 2019-07-31 | $-688.66K | $-5.12 Million | 7.434x | +241.81% |
| 2018-07-31 | $945.02K | $-4.95 Million | -5.242x | -105.75% |
| 2017-07-31 | $750.23K | $-1.91 Million | -2.548x | -27.07% |
| 2016-07-31 | $787.11K | $-1.58 Million | -2.005x | -95.86% |
| 2015-07-31 | $1.16 Million | $-1.19 Million | -1.024x | -100.29% |
| 2014-07-31 | $-1.13K | $-397.42K | 352.638x | +862188.34% |
| 2013-07-31 | $9.33 Million | $-381.80K | -0.041x | -7.25% |
| 2012-07-31 | $10.03 Million | $-382.74K | -0.038x | +32.46% |
| 2011-07-31 | $11.63 Million | $-656.68K | -0.056x | +74.43% |
| 2010-07-31 | $1.44 Million | $-318.63K | -0.221x | -42.45% |
| 2009-07-31 | $974.50K | $-151.05K | -0.155x | +36.89% |
| 2008-07-31 | $365.17K | $-89.68K | -0.246x | -25.01% |
| 2007-07-31 | $446.71K | $-87.76K | -0.196x | -1492.27% |
| 2006-07-31 | $79.82K | $1.13K | 0.014x | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more